The Kі-67 marker for assessing the effectiveness of systemic or regional neoadjuvant polychemotherapy in patients with locally advanced breast cancer
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13303Keywords:
immunohistochemistry, locally advanced breast cancer, neoadjuvant polychemotherapy, Кі-67Abstract
Summary. Over the past decades, breast cancer (BC) is the most common cancer and one of the key causes of mortality and disability among women in developed countries. Aim: Determination of the role of Ki-67 index in assessing the quality of neoadjuvant polychemotherapy treatment using regional or systemic delivery routes of pharmacological agents in patients with locally advanced breast cancer (LABC). Materials and Methods: The retrospective analysis of 30 clinical trials of LABC treatment based on selective intra-arterial therapy in patients with BC (T4A-DN0-3M0) was used. Results: The decrease in Ki-67 level in LABC after selective intra-arterial polychemotherapy was more pronounced than after systemic polychemotherapy. No correlation of the tumor metastatic potential with a Ki-67 level was detected. Conclusion: Assessment of Ki-67 expression allows to evaluate effectively the biological properties of the tumor, predict the course of the disease and choose the optimal tactics of neoadjuvant polychemotherapy (regional or systemic variant) as part of integrated antitumor treatment.
References
Yamauchi H, Woodward WA, Valero V, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012; 17: 891–9.
Wirtz HS, Buist DSM, Gralow JR, et al. Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 2013; 22: 1588–99.
Ording AG, Garne JP, Nyström PMW, et al. Hospital recorded morbidity and breast cancer incidence: a nationwide population-based case-control study. PLoS One 2012; 7: e47329.
Landercasper J, Bailey L, Buras R, et al. The American Society of Breast Surgeons and quality payment programs: ranking, defining, and benchmarking more than 1 million patient quality measure encounters. Ann Surg Oncol 2017; 24: 3093–106.
Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and following breast cancer treatment. CA Cancer J Clin 2017; 67: 194–232.
Picon‐Ruiz M, Morata‐Tarifa C, Valle‐Goffin JJ, et al. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin 2017; 67: 378–97.
Sueishi M, Takagi M, Yoneda Y. The forkhead-associated domain of Ki-67 antigen interacts with the novel kinesin-like protein Hklp2. J Biol Chem 2000; 275: 28888–92.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13–20.
Viale G, Regan MM, Mastropasqua MG, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Nat Cancer Inst 2009; 100: 207–12.
Yerushalmi R, Woods R, Ravdin PM, et al. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174–83.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.